File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Inhibitors of Influenza A Virus Polymerase

TitleInhibitors of Influenza A Virus Polymerase
Authors
Issue Date2018
PublisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journal/aidcbc
Citation
ACS Infectious Diseases, 2018, v. 4 n. 3, p. 218-223 How to Cite?
AbstractThe propensity of influenza virus to develop resistance to commonly prescribed drugs highlights the need for continuing development of new therapeutics. Biological and structural investigations of the enzymatic and interaction domains among influenza A virus polymerase subunits have broadened the target reservoir for drug screening. With the wealth of knowledge from these studies, identification of small-molecule and peptidic inhibitors that specifically abrogate polymerase activity or disrupt the polymerase assembly has emerged as an innovative and promising approach. Importantly, those domains are highly conserved among influenza subtypes and thus minimize the emergence of drug resistant mutants. An overview of the reported enzymatic inhibitors and protein-protein disruptors has been provided, in our effort to facilitate the development of next-generation anti-influenza therapeutics. © 2018 American Chemical Society.
Persistent Identifierhttp://hdl.handle.net/10722/276334
ISSN
2017 Impact Factor: 4.325

 

DC FieldValueLanguage
dc.contributor.authorYuan, S-
dc.contributor.authorWen, LR-
dc.contributor.authorZhou, J-
dc.date.accessioned2019-09-10T03:00:59Z-
dc.date.available2019-09-10T03:00:59Z-
dc.date.issued2018-
dc.identifier.citationACS Infectious Diseases, 2018, v. 4 n. 3, p. 218-223-
dc.identifier.issn2373-8227-
dc.identifier.urihttp://hdl.handle.net/10722/276334-
dc.description.abstractThe propensity of influenza virus to develop resistance to commonly prescribed drugs highlights the need for continuing development of new therapeutics. Biological and structural investigations of the enzymatic and interaction domains among influenza A virus polymerase subunits have broadened the target reservoir for drug screening. With the wealth of knowledge from these studies, identification of small-molecule and peptidic inhibitors that specifically abrogate polymerase activity or disrupt the polymerase assembly has emerged as an innovative and promising approach. Importantly, those domains are highly conserved among influenza subtypes and thus minimize the emergence of drug resistant mutants. An overview of the reported enzymatic inhibitors and protein-protein disruptors has been provided, in our effort to facilitate the development of next-generation anti-influenza therapeutics. © 2018 American Chemical Society.-
dc.languageeng-
dc.publisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journal/aidcbc-
dc.relation.ispartofACS Infectious Diseases-
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in [JournalTitle], copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles on Request author-directed link to Published Work, see http://pubs.acs.org/page/policy/articlesonrequest/index.html].-
dc.titleInhibitors of Influenza A Virus Polymerase-
dc.typeArticle-
dc.identifier.emailYuan, S: yuansf@hku.hk-
dc.identifier.emailZhou, J: jiezhou@hku.hk-
dc.identifier.authorityZhou, J=rp01412-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1021/acsinfecdis.7b00265.-
dc.identifier.pmid29355011-
dc.identifier.scopuseid_2-s2.0-85043464032-
dc.identifier.hkuros302709-
dc.identifier.volume4-
dc.identifier.issue3-
dc.identifier.spage218-
dc.identifier.epage223-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats